Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

folium builds on the data wrangling strengths of the Python ecosystem and the mapping strengths of the Leaflet.js library. Manipulate your data in Python, then visualize it in a Leaflet map via folium ...

BERLIN, Jan 17 (Reuters) - German authorities are to lift an emergency ordinance to stop the spread of the livestock illness foot-and-mouth disease at the end of the day, the agriculture ministry ...

Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...

Inaxaplin targets APOL1-mediated kidney disease, which affects around ... are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Inaxaplin targets APOL1-mediated kidney disease ... before its PDUFA date. Vertex could win approval for suzetrigine early, too. Keith Speights has positions in Vertex Pharmaceuticals.

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...